Clinical Trial Detail

NCT ID NCT04413123
Title Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bradley A. McGregor
Indications

collecting duct carcinoma

papillary renal cell carcinoma

renal cell carcinoma

sarcomatoid renal cell carcinoma

chromophobe renal cell carcinoma

Therapies

Cabozantinib + Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.